secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001104659-23-039764
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma raises $50M in convertible notes and $75M contingent royalty sale
--------------------------------------------------------------------------------

- Issued $50M principal of 6.0% Convertible Senior Notes due 2029 to RTW Investments.
- Notes convertible at ~$5.23 per share (191.0548 shares per $1,000 principal).
- Interest payable quarterly; PIK option for first 3 years; secured by substantially all assets.
- Royalty Purchase Agreement: RTW to pay $75M for tiered royalties on U.S. etripamil sales post-FDA approval.
- Proceeds support development of etripamil; notes mature March 31, 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/tm2311047d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer